Creative Bioarray has launched its flagship hERG safety assay service, a development aimed at enhancing drug safety assessment in pharmaceutical research. The service utilizes advanced assay methods to evaluate potential cardiotoxicity of drug candidates, addressing a critical safety concern in drug development.
Blockage of hERG potassium channels, which play a crucial role in cardiac action potentials and rhythms, can lead to life-threatening cardiac side effects. Creative Bioarray's hERG safety assay optimizes traditional screening methods by integrating modern technologies and processes to deliver high-throughput, reliable results. The company provides clients with detailed data interpretations to help scientists optimize lead compounds while reducing the risk of late-stage drug development failure due to cardiotoxicity.
"Our hERG safety testing service provides a vital tool for pharmaceutical companies and researchers looking to streamline their drug development process," said Hannah Cole, a spokesperson for Creative Bioarray. "Our advanced testing methods provide the critical information needed to make informed decisions and ensure the safety of new therapies."
The service can be integrated into early stages of drug development, potentially improving project efficiency and helping bring safe drugs to market faster. This development is designed to benefit a wide range of stakeholders in the pharmaceutical industry, including biotechnology companies, contract research organizations, and academic institutions.
Creative Bioarray has cultivated a team of experienced experts with extensive expertise in pharmacology, electrophysiology, and drug safety assessment. This expertise provides clients with not only highly accurate assays but also comprehensive analysis and guidance throughout the research process. The company's approach represents a significant advancement in preclinical safety testing, addressing one of the most common causes of drug candidate failure during development.
For the pharmaceutical industry, this service could potentially reduce development costs by identifying problematic compounds earlier in the pipeline, before significant resources are invested in clinical trials. The ability to accurately assess hERG channel interaction has become increasingly important as regulatory agencies worldwide emphasize cardiac safety in drug approval processes.
In addition to hERG safety testing, Creative Bioarray offers a range of other bioassays, customized services, and products to meet specific needs of modern research environments. The launch of this specialized service reflects the growing demand for sophisticated safety assessment tools in an industry where development timelines and safety requirements continue to intensify.
